A potential novel therapeutic agent for bladder cancer is vasoactive intestinal peptide (VIP), which is a 28-amino acid peptide that has multiple therapeutic actions, including bronchodilatory and anti-inflammatory properties (3, 4). Here, VIP is linked to urinary bladder carcinoma.